Massachusetts General Hospital

CRISPR, Massachusetts General Hospital partner on CRISPR/Cas9 in T cell cancer therapies

Thursday, August 24, 2017

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Massachusetts General Hospital Cancer Center (MGHCC), a scientific and clinical institution, have entered into a two-year research collaboration and license option agreement to develop novel T cell therapies for cancer. As part of the collaboration, CRISPR/Cas9 gene editing will be utilized to improve upon current T cell therapies in development, ultimately addressing unmet needs in both hematologic and solid tumors. Marcela V. Maus, M.D., Ph.D., director of the Cellular Immunotherapy Program at MGHCC and Assistant Professor of Medicine at Harvard Medical, will lead the scientific work at MGH.

[Read More]

Initial results from Dana-Farber Cancer Institute personalized neoantigen vaccine published

Friday, July 7, 2017

Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, has announced the publication of an article in Nature presenting initial feasibility, safety, immunogenicity and clinical outcomes for a personalized neoantigen vaccine in patients with adjuvant melanoma. The article entitled ‘An immunogenic personal neoantigen vaccine for patients with melanoma’ (DOI 10.1038/nature22991) demonstrates the validity of the neoantigen vaccine approach as an effective immunotherapy.

[Read More]

Ergomed appoints Dr Dan Weng as CEO

Friday, June 23, 2017

Ergomed, a company dedicated to the provision of specialized services to the pharmaceutical industry and the development of new drugs, announced the strengthening of its executive team with the appointment of Dr. Dan Weng as its new chief executive officer and a board director of Ergomed. Dr. Weng joins Ergomed with effect from 1 July 2017 from EPS Holdings (EPSHD), a global CRO listed on the Tokyo Stock Exchange.

[Read More]

MDA awards more than $7M in new research grants

Friday, March 10, 2017

The Muscular Dystrophy Association has announced the award of 29 new R&D grants totaling more than $7 million and targeted to impact the state of the science and accelerate the development of treatments for muscular dystrophy, ALS and related life-threatening diseases. The investment reflects MDA’s continued efforts to refocus resources in order to double research spending on drug development and clinical trials by 2020.

[Read More]

Bristol-Myers Squibb appoints Dr. Thomas J. Lynch, Jr., EVP and CSO

Thursday, March 9, 2017

Bristol-Myers Squibb has appointed Dr. Thomas J. Lynch, Jr., executive vice president and chief scientific officer, effective March 16, 2017. He succeeds Dr. Francis Cuss, who will retire from the company. Dr. Cuss will serve as an advisor to the company for the next three months to ensure a seamless transition. In connection with today’s announcement, Dr. Lynch will step down from the Board of Directors of Bristol-Myers Squibb, effective March 15, 2017.

[Read More]

Christiana Care Health System’s Gene Editing Institute awarded genomic cancer research grant from BIRD Foundation

Tuesday, January 31, 2017

For its enormous potential to accelerate the development of personalized cancer therapies, the Gene Editing Institute of Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute has been awarded a grant of $900,000 from the U.S.-Israel Binational Industrial Research and Development (BIRD) Foundation in partnership with the biotechnology company NovellusDx.

[Read More]